Hydrogen Gas Boosts Cancer Immunotherapy Success in Lung Cancer Patients

TL;DR

Inhaling hydrogen gas appears to improve the survival of lung cancer patients treated with the immune therapy drug nivolumab by boosting the energy production in immune cells.

Key Finding

Lung cancer patients treated with hydrogen gas combined with nivolumab had significantly longer overall survival compared to those receiving nivolumab alone, with the best outcomes in patients showing increased coenzyme Q10 levels and reduced exhausted T cell markers.

Summary

This study examined whether hydrogen gas combined with nivolumab (an immunotherapy drug) improves outcomes in lung cancer patients. Researchers measured immune cell markers and mitochondrial function (using coenzyme Q10 as a measure) in 42 patients receiving both treatments compared to 14 receiving nivolumab alone. Patients who received hydrogen gas with nivolumab lived longer on average, and those whose immune cells showed specific improvements (lower exhaustion markers and higher mitochondrial function) had the best outcomes.

Practical Takeaway

While this human study suggests hydrogen gas may enhance immunotherapy effectiveness in lung cancer, the small sample size (42 patients receiving both treatments) and lack of reported study duration limit how much weight can be placed on these findings. This early evidence indicates hydrogen gas warrants further investigation as a potential complement to cancer immunotherapy, but more rigorous, larger studies are needed before any clinical recommendations can be made.

Abstract (excerpt)

As previously reported, hydrogen gas improves the prognosis of patients with cancer by restoring exhausted CD8+ T cells into active CD8+ T cells, possibly by activating mitochondria. As mitochondrial activators exhibit synergistic effects with nivolumab, the current study investigated whether…

Read the full abstract via DOI